Recruiting
MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial
NCT06060873· University of Southern California· Source
Contact: Ileana Aldana
Active, not recruiting
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
NCT05514990· Phase 1/2· University of Southern California· Source
Recruiting
Confronting Cancer as a Community
NCT06063928· University of Southern California· Source
Contact: Ashley Noriega
Recruiting
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597· Phase 3· SWOG Cancer Research Network· Source
Contact: Varsha Tulpule (principal investigator)
Active, not recruiting
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
NCT04484818· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04435756· SWOG Cancer Research Network· Source
Active, not recruiting
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT04094688· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
NCT03757949· Phase 3· SWOG Cancer Research Network· Source
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025· Phase 3· SWOG Cancer Research Network· Source
Contact: Siamak Daneshmand (principal investigator)
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928· SWOG Cancer Research Network· Source
Active, not recruiting
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
NCT03330821· Phase 1/2· University of Southern California· Source
Active, not recruiting
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
NCT03092856· Phase 2· University of Southern California· Source
Active, not recruiting
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
NCT03091660· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
NCT02595424· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· Phase 3· NRG Oncology· Source
Active, not recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
S0820, Adenoma and Second Primary Prevention Trial
NCT01349881· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01415752· Phase 2· Eastern Cooperative Oncology Group· Source
Active, not recruiting
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT01368588· Phase 3· Radiation Therapy Oncology Group· Source
Active, not recruiting
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· Phase 2· Radiation Therapy Oncology Group· Source
Active, not recruiting
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00956007· Phase 3· Radiation Therapy Oncology Group· Source